Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers

Ajit Thakur, Scott Fitzpatrick, Abeyat Zaman, Kapilan Kugathasan, Ben Muirhead, Gonzalo Hortelano, Heather Sheardown

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However, recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability, while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies for the development of a 'universal' siRNA delivery system for clinical applications.

Original languageEnglish
Article number7
JournalJournal of Biological Engineering
Volume6
DOIs
Publication statusPublished - Jun 11 2012
Externally publishedYes

Fingerprint

RNA
Small Interfering RNA
Gene expression
Pharmaceutical Preparations
Intraocular Injections
Gene Expression
Eye Diseases
Drug delivery
Biological Availability
Pipelines
Technology
Therapeutics

Keywords

  • Biomaterials
  • Drug delivery
  • Endosomal escape
  • Nanocarriers
  • Ocular siRNA delivery
  • RNAi
  • siRNA

ASJC Scopus subject areas

  • Biomedical Engineering
  • Environmental Engineering
  • Cell Biology
  • Molecular Biology

Cite this

Strategies for ocular siRNA delivery : Potential and limitations of non-viral nanocarriers. / Thakur, Ajit; Fitzpatrick, Scott; Zaman, Abeyat; Kugathasan, Kapilan; Muirhead, Ben; Hortelano, Gonzalo; Sheardown, Heather.

In: Journal of Biological Engineering, Vol. 6, 7, 11.06.2012.

Research output: Contribution to journalArticle

Thakur, Ajit ; Fitzpatrick, Scott ; Zaman, Abeyat ; Kugathasan, Kapilan ; Muirhead, Ben ; Hortelano, Gonzalo ; Sheardown, Heather. / Strategies for ocular siRNA delivery : Potential and limitations of non-viral nanocarriers. In: Journal of Biological Engineering. 2012 ; Vol. 6.
@article{776e0f037ae144b9b9d48b8802d87a03,
title = "Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers",
abstract = "Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However, recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability, while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies for the development of a 'universal' siRNA delivery system for clinical applications.",
keywords = "Biomaterials, Drug delivery, Endosomal escape, Nanocarriers, Ocular siRNA delivery, RNAi, siRNA",
author = "Ajit Thakur and Scott Fitzpatrick and Abeyat Zaman and Kapilan Kugathasan and Ben Muirhead and Gonzalo Hortelano and Heather Sheardown",
year = "2012",
month = "6",
day = "11",
doi = "10.1186/1754-1611-6-7",
language = "English",
volume = "6",
journal = "Journal of Biological Engineering",
issn = "1754-1611",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Strategies for ocular siRNA delivery

T2 - Potential and limitations of non-viral nanocarriers

AU - Thakur, Ajit

AU - Fitzpatrick, Scott

AU - Zaman, Abeyat

AU - Kugathasan, Kapilan

AU - Muirhead, Ben

AU - Hortelano, Gonzalo

AU - Sheardown, Heather

PY - 2012/6/11

Y1 - 2012/6/11

N2 - Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However, recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability, while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies for the development of a 'universal' siRNA delivery system for clinical applications.

AB - Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However, recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability, while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies for the development of a 'universal' siRNA delivery system for clinical applications.

KW - Biomaterials

KW - Drug delivery

KW - Endosomal escape

KW - Nanocarriers

KW - Ocular siRNA delivery

KW - RNAi

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=84861993060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861993060&partnerID=8YFLogxK

U2 - 10.1186/1754-1611-6-7

DO - 10.1186/1754-1611-6-7

M3 - Article

C2 - 22686441

AN - SCOPUS:84861993060

VL - 6

JO - Journal of Biological Engineering

JF - Journal of Biological Engineering

SN - 1754-1611

M1 - 7

ER -